ProPhase Labs, Inc. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
ProPhase Labs, Inc. (PRPH) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $1.34 million as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2026-08-19
- 2026-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $1.34M.
- 2026-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $1.66M.
- 2025-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $1.98M.
- 2025-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $2.29M.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization | Finance Lease, Right-of-Use Asset, after Accumulated Amortization as first filed |
|---|---|---|
| 2026-06-30 | $1.34M 10-Q · filed 2026-08-19 | |
| 2026-03-31 | $1.66M 10-Q/A · filed 2026-07-09 | |
| 2025-12-31 | $1.98M 10-Q · filed 2026-08-19 | |
| 2025-09-30 | $2.29M 10-Q · filed 2025-11-19 | |
| 2025-06-30 | $3.46M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $3.85M 10-Q · filed 2025-05-20 | |
| 2024-12-31 | $4.24M 10-K · filed 2026-06-01 | |
| 2024-09-30 | $7.55M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $8.72M 10-Q · filed 2024-08-14 | |
| 2024-05-14 | $500.00K 10-K · filed 2025-04-01 | $700.00K 10-Q · filed 2024-08-14 |
| 2024-03-31 | $5.42M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $5.81M 10-K · filed 2025-04-01 | |
| 2023-09-30 | $6.20M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $1.45M 10-Q · filed 2023-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |